Inactive Instrument
Organovo Holdings Inc Stock NYSE
Stocks
US68620A1043
Biotechnology & Medical Research
|
End-of-day quote
NYSE
|
||
| - USD | - |
|
| 09-01 | VivoSim Labs Plans To Develop Rat Liver Model To Complement NAMkind Human Liver Platform | CI |
| 08-12 | VivoSim Labs, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
| Market Cap | 3.15M 2.8M 2.62M 2.38M 4.49M 303M 4.55M 31.64M 12.25M 154M 11.82M 11.56M 496M | P/E 2025 |
-1.32x | P/E 2026 | -0.27x |
|---|---|---|---|---|---|
| Enterprise Value | -1.31M -1.16M -1.09M -992K -1.87M -126M -1.89M -13.17M -5.1M -64.27M -4.92M -4.81M -206M | EV / Sales 2025 |
-43,384,333x | EV / Sales 2026 | -5,569,580x |
| Free-Float |
97.33% | Yield 2025 * |
-
| Yield 2026 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Keith Murphy
CEO | Chief Executive Officer | 55 | 2006-12-31 |
Norman Staskey
DFI | Director of Finance/CFO | 56 | 2024-12-29 |
Amar Sethi
CTO | Chief Tech/Sci/R&D Officer | - | 2026-01-05 |
| Director | Title | Age | Since |
|---|---|---|---|
Keith Murphy
CHM | Chairman | 55 | 2006-12-31 |
Adam Stern
BRD | Director/Board Member | 61 | 2012-01-31 |
Douglas Cohen
BRD | Director/Board Member | 55 | 2020-09-14 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +4.16% | -0.36% | +49.37% | +94.17% | 74.46B | ||
| -0.61% | +0.81% | +27.25% | +80.21% | 60.14B | ||
| -2.54% | -1.65% | +4.86% | +33.32% | 48.15B | ||
| -2.80% | -4.81% | +28.47% | +35.03% | 44.25B | ||
| +0.90% | +3.72% | +352.03% | +692.13% | 43.99B | ||
| -1.76% | +0.06% | +7.47% | +101.79% | 41.61B | ||
| +3.32% | +3.49% | +11.18% | +51.23% | 29.97B | ||
| +4.77% | +6.16% | +36.77% | +22.78% | 29.31B | ||
| -3.72% | -9.62% | -25.41% | +333.01% | 24.93B | ||
| Average | +0.19% | +1.97% | +54.67% | +160.41% | 44.09B | |
| Weighted average by Cap. | +0.36% | +1.83% | +58.94% | +151.66% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 0.14 0.13 0.12 0.11 0.21 13.86 0.21 1.45 0.56 7.06 0.54 0.53 22.68 | 0.13 0.12 0.11 0.1 0.19 12.61 0.19 1.32 0.51 6.42 0.49 0.48 20.63 |
| Net income | -2.49M -2.21M -2.07M -1.88M -3.55M -240M -3.59M -25M -9.68M -122M -9.34M -9.14M -392M | -13.84M -12.3M -11.5M -10.48M -19.73M -1.33B -20M -139M -53.85M -679M -51.97M -50.85M -2.18B |
| Net Debt | -10.24M -9.1M -8.51M -7.75M -14.59M -986M -14.8M -103M -39.84M -502M -38.45M -37.62M -1.61B | -4.46M -3.96M -3.7M -3.38M -6.35M -429M -6.44M -44.81M -17.35M -219M -16.74M -16.38M -702M |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
















